It’s lucky for Madison, Wisconsin’s bioinformatics and genotyping firm EraGen Biosciences that new president and CEO Irene Hrusovsky, a self-proclaimed health nut who’s always been interested in genetics, has a thing for commercialization. A pediatrician by training, she got her industry start at Abbott Laboratories almost 25 years ago. The mentality there was to commercialize new technology or a new business as soon as possible: “When it looked feasible, they would fund a venture,” she says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.